vestimИзвестия Национальной академии наук Беларуси. Серия медицинских наукProceedings of the National Academy of Sciences of Belarus, Medical series1814-60232524-2350The Republican Unitary Enterprise Publishing House "Belaruskaya Navuka"10.29235/1814-6023-2024-21-2-138-148vestim-966Research ArticleКЛИНИЧЕСКАЯ И ЭКСПЕРИМЕНТАЛЬНАЯ МЕДИЦИНАCLINICAL AND EXPERIMENTAL MEDICINEОсобенности распространения полиморфных вариантов генов CYP2C19, P2RY12, ITGB3, ITGA2 и eNOS3 среди пациентов с инфарктом миокардаFrequency of CYP2C19, P2RY12, ITGB3, ITGA2, and eNOS3 gene polymorphism in patients with myocardial infarctionhttps://orcid.org/0000-0003-2126-5246ПронькоТ. П.PronkoТ. Р.

Пронько Татьяна Павловна – канд. мед. наук, доцент, заведующий кафедрой

ул. Горького, 80, 230009, г. Гродно

Tatyana P. Pronko ‒ Ph. D. (Med.), Associate Professor, Head of the Department

80, Gorky Str., 230009, Grodno

tanya_pronko@mail.ruhttps://orcid.org/0000-0002-1706-1243СнежицкийВ. А.SnezhitskiyV. А.

Снежицкий Виктор Александрович ‒ член-корресспондент, д-р мед. наук, профессор

ул. Горького, 80, 230009, г. Гродно

 

Viktor A. Snezhitskiy ‒ Corresponding Member, D. Sc. (Med.), Professor

80, Gorky Str., 230009, Grodno

vsnez@mail.ruhttps://orcid.org/0000-0002-3337-4231СтепуроТ. Л.StsiapuraТ. L.

Степуро Татьяна Леонидовна – канд. биол. наук, доцент

ул. Горького, 80, 230009, г. Гродно

Tatsiana L. Stsiapura ‒ Ph. D. (Biol.), Associate Professor

80, Gorky Str., 230009, Grodno

tatianastepuro31@gmail.comhttps://orcid.org/0000-0001-9998-4350ГорчаковаО. В.GorchakovaО. V.

Горчакова Ольга Владимировна ‒ ст. науч. сотрудник

ул. Горького, 80, 230009, г. Гродно

Olga V. Gorchakova ‒ Senior Researcher

80, Gorky Str., 230009, Grodno

daniil_go@inbox.ruГродненский государственный медицинский университетGrodno State Medical University202427052024212138148Copyright © Пронько Т.П., Снежицкий В.А., Степуро Т.Л., Горчакова О.В., 20242024Пронько Т.П., Снежицкий В.А., Степуро Т.Л., Горчакова О.В.Pronko Т.Р., Snezhitskiy V.А., Stsiapura Т.L., Gorchakova О.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vestimed.belnauka.by/jour/article/view/966

Цель исследования – оценить распространение полиморфных вариантов G681A (*2) гена CYP2C19, H1/H2 гена P2RY12, T1565C гена ITGB3, С807Т гена ITGA2 и T786C гена eNOS3 в популяции Гродненского региона и изучить их ассоциации с инфарктом миокарда (ИМ).

В исследование были включены 493 человека ‒ 400 пациентов с ИМ (возраст от 31 года до 74 лет) и 93 человека контрольной группы (возраст от 32 до 60 лет). Данные обследований (общеклинических и генотипирования, выполненного методом ПЦР) проанализированы с помощью программы STATISTICA 10.0. Распространенность носительства генотипов, ассоциированных с высокой остаточной реактивностью тромбоцитов и вариабельностью ответа на двойную антитромбоцитарную терапию, среди пациентов с ИМ по полиморфному локусу G681A гена CYP2C19 (GA + AA) составила 25,2 %, по полиморфному локусу H1/H2 гена P2RY12 (H1/H2 + H2/H2) – 40,0, по полиморфному локусу C807T гена ITGA2 (CT + TT) – 65,8, по полиморфному локусу T1565C гена ITGB3 (TC + CC) – 25,5, по полиморфному локусу T786C гена eNOS (TC  + CC) – 69,2 %, а среди лиц контрольной группы ‒ 18,3; 46,2; 60,2; 37,6; 48,4 % соответственно. У пациентов с ИМ при сравнении с контрольной группой реже встречался генотип ТТ гена eNOS (χ2 = 13,6, р = 0,0002), но чаще выявлялись генотип СС гена eNOS (χ2 = 5,4, p = 0,02) и аллель 786C гена eNOS (χ2 = 15,1, p = 0,0001). Носительство аллеля 786C гена eNOS увеличивало риск развития ИМ в исследованной выборке (ОШ = 2,0; 95 % ДИ: 1,41‒2,82; p = 0,0001). Не выявлено гендерных различий по распределению генотипов и аллелей между пациентами исследуемых групп, а также различий по носительству в зависимости от количества комбинаций минорных аллелей у лиц контрольной группы и у пациентов с ИМ. Наиболее часто встречающиеся комбинации минорных аллелей в обеих группах были сопоставимы.

The aim of the study was to assess the distribution of polymorphic variants G681A (*2) of the CYP2C19 gene, H1/H2 of the P2RY12 gene, T1565C of the ITGB3 gene, C807T of the ITGA2 gene, and T786C of the eNOS3 gene in the population of the Grodno region, and to study their associations with myocardial infarction (MI). The study of the population consists of 493 people, including 400 patients with MI aged 31 to 74 years and 93 people of the control group aged 32 to 60 years. Research data (clinical and genotyping performed by polymerase chain reaction) were analyzed using STATISTICA 10.0 software. The prevalence of carriage of genotypes associated with high residual platelet reactivity and variability in response to dual antiplatelet therapy among patients with MI was 25.2 % for the G681A polymorphic locus of the CYP2C19 gene (GA + AA), and for the H1/H2 polymorphic locus of the P2RY12 gene (H1/H2 + H2/H2) – 40.0 %, for the C807T polymorphic locus of the ITGA2 gene (CT + TT) – 65.8, for the T1565C polymorphic locus of the ITGB3 gene (TC + CC) – 25.5, for the polymorphic locus T786C of the eNOS gene (TC + CC) – 69.2 %. Among the individuals of the control group, the frequency of occurrence of these genotypes was 18.3, 46.2, 60.2, 37.6, 48.4 %, respectively. In patients with MI, compared to the control group, the TT genotype of the eNOS gene was less common (χ2   =  13.6, p  =  0.0002), the CC genotype of the eNOS gene (χ2 = 5.4, p = 0.02) and the allele 786C of the eNOS gene (χ2 = 15.1, p = 0.0001) were more often detected. The carriage of the 786C allele of the eNOS gene increased the risk of MI in the studied population (OR = 2.0, 95 % CI: 1.41‒2.82, p = 0.0001). Gender differences were not found in the distribution of genotypes and alleles within the studied groups. There were no differences in carriage by the number of combinations of minor alleles between the control group and patients with MI. The most common combinations of minor alleles in both groups were comparable.

полиморфизм генов CYP2C19P2RY12ITGB3ITGA2eNOS3инфаркт миокардарolymorphism of CYP2C19P2RY12ITGB3ITGA2eNOS3 genesmyocardial infarctionReferencesMolecular pathways used by platelets to initiate and accelerate atherogenesis / S. Lindemann [et al.] // Curr. Opin. Lipidol. – 2007. – Vol. 18, N 5. – P. 566–573. https://doi.org/10.1097/MOL.0b013e3282ef7c1eLindemann S., Kramer B., Daub K., Stellos K., Gawaz M. Molecular pathways used by platelets to initiate and accelerate atherogenesis. Current Opinion in Lipidology, 2007, vol. 18, no. 5, pp. 566–573. https://doi.org/10.1097/MOL.0b013e3282ef7c1eFontana, P. Platelet function test use for patients with coronary artery disease in the early 2020s / P. Fontana, M. Roffi, J. L. Reny // J. Clin. Med. – 2020. – Vol. 9, N 1. – Art. 194. https://doi.org/10.3390/jcm9010194Fontana P., Roffi M., Reny J. L. Platelet function test use for patients with coronary artery disease in the early 2020s. Journal of Clinical Medicine, 2020, vol. 9, no. 1, art. 194. https://doi.org/10.3390/jcm9010194Кропачева, Е. С. Фармакогенетика антитромботических препаратов: современное состояние проблемы / Е. С. Кропачева // Атеротромбоз. – 2018. – № 2. – С. 115–129.Kropacheva E. S. Pharmacogenetics of antithrombotic drugs: current state of the problem. Aterotromboz [Аtherothrombosis], 2018, no. 2, pp. 115–129 (in Russian).Impact of genetic polymorphisms on platelet function and response to anti platelet drugs / T. Strisciuglio [et al.] // Cardiovasc. Diagn. Ther. – 2018. – Vol. 8, N 5. ‒ P. 610–620. https://doi.org/10.21037/cdt.2018.05.06Strisciuglio T., Franco D., Di Gioia G., De Biase C., Morisco C., Trimarco B., Barbato E. Impact of genetic polymorphisms on platelet function and response to anti platelet drugs. Cardiovascular Diagnosis and Therapy, 2018, vol. 8, no. 5, pp. 610–620. https://doi.org/10.21037/cdt.2018.05.06Cytochrome allelic variants and clopidogrel metabolism in cardiovascular diseases therapy / M. Jarrar [et al.] // Mol. Biol. Rep. – 2016. – Vol. 43, N 6. – P. 473–484. https://doi.org/10.1007/s11033-016-3983-1Jarrar M., Behl S., Manyam G., Ganah H., Nazir M., Nasab R., Moustafa K. Cytochrome allelic variants and clopidogrel metabolism in cardiovascular diseases therapy. Molecular Biology Reports, 2016, vol. 43, no. 6, pp. 473–484. https://doi.org/10.1007/s11033-016-3983-1Мультиэтнический анализ кардиологических фармакогенетических маркеров генов цитохрома Р450 и мембранных транспортеров в российской популяции / К. Б. Мирзаев [и др.] // Рациональная фармакотерапия в кардиологии. – 2019. ‒ Т. 15, № 3. – С. 393–406.Mirzaev K. B., Fedorinov D. S., Ivashchenko D. V., Sychev D. A. Multiethnic analysis of cardiological pharmacogenetic markers of cytochrome P450 genes and membrane transporters in the Russian population. Ratsional’naya farmakoterapiya v kardiologii [Rational pharmacotherapy in cardiology], 2019, vol. 15, no. 3, pp. 393–406 (in Russian).Purinergic receptor P2Y, G protein coupled, 12 gene variants and risk of incident ischemic stroke, myocardial infarction, and venous thromboembolism / R. Y. Zee [et al] // Atherosclerosis. – 2008. – Vol. 197, N 2. – P. 694–699. https://doi.org/10.1016/j.atherosclerosis.2007.07.001Zee R. Y., Michaud Sh. E., Diehl K. A., Chasman D. I. [et al.]. Purinergic receptor P2Y, G protein coupled, 12 gene variants and risk of incident ischemic stroke, myocardial infarction, and venous thromboembolism. Atherosclerosis, 2008, vol. 197, no. 2, pp. 694–699. https://doi.org/10.1016/j.atherosclerosis.2007.07.001P2Y12 receptor gene polymorphism and the risk of resistance to clopidogrel: A meta-analysis and review of the literature / G. Cui [et al.] // Adv. Clin. Exp. Med. – 2017. – Vol. 26, N 2. – P. 343–349. https://doi.org/10.17219/acem/63745Cui G., Zhang Sh., Zou J., Chen Y., Chen H. P2Y12 receptor gene polymorphism and the risk of resistance to clopidogrel: A metaanalysis and review of the literature. Advances in Clinical and Experimental Medicine, 2017, vol. 26, no. 2, pp. 343–349. https://doi.org/10.17219/acem/63745Influence of genetic and epigenetic factors of P2Y12 receptor on the safety and efficacy of antiplatelet drugs / D. Danielak [et al.] // Cardiovasc. Drugs Ther. – 2022. https://doi.org/10.1007/s10557-022-07370-8Danielak D., Pawlak K., Główka F., Karaźniewicz-Łada M. Influence of genetic and epigenetic factors of P2Y12 receptor on the safety and efficacy of antiplatelet drugs. Cardiovascular Drugs and Therapy, 2022. https://doi.org/10.1007/s10557-022-07370-8Identification of ITGA2B and ITGB3 single-nucleotide polymorphisms and their influences on the platelet function / Q. Xiang [et al.] // Biomed. Res. Int. – 2016. – Vol. 2016. – Art. ID 5675084. https://doi.org/10.1155/2016/5675084Xiang Q., Ji Sh-D., Zhang Zh., Zhao X., Cui Y-M. Identification of ITGA2B and ITGB3 single-nucleotide polymorphisms and their influences on the platelet function. BioMed Research International, 2016, vol. 2016, art. ID 5675084. https://doi.org/10.1155/2016/5675084Evaluation of platelet reactivity during combined antiplatelet therapy in patients with stable coronary artery disease in relation to diabetes type 2 and the GPIIB/IIIA receptor gene polymorphism / M. Jastrzebska [et al.] // J. Physiol. Pharmacol. – 2019. – Vol. 70, N 2. – P. 175–185. https://doi.org/10.26402/jpp.2019.2.01Jastrzebska M., Lisman D., Szelepajlo A., Oledzki S., Chelstowski K., Clark J. S., Siennicka A. Evaluation of platelet reactivity during combined antiplatelet therapy in patients with stable coronary artery disease in relation to diabetes type 2 and the GPIIB/IIIA receptor gene polymorphism. Journal of Physiology and Pharmacology, 2019, vol. 70, no. 2, pp. 175–185. https://doi.org/10.26402/jpp.2019.2.01The association of four common polymorphisms from four candidate genes (COX-1, COX-2, ITGA2B, ITGA2) with aspirin insensitivity: A meta-analysis / Z. Weng [et al.] // PLOS ONE. – 2013. – Vol. 8, N 11. – P. e78093. – https://doi.org/10.1371/journal.pone.0078093Weng Z., Li X., Li Y., Lin J., Peng F., Niu W. The association of four common polymorphisms from four candidate genes (COX-1, COX-2, ITGA2B, ITGA2) with aspirin insensitivity: A meta-analysis. PLOS ONE, 2013, vol. 8, no. 11, p. e78093. https://doi.org/10.1371/journal.pone.0078093Власов, Т. Д. Эндотелиальная дисфункция: от частного к общему. Возврат к «старой парадигме»? / Т. Д. Власов, И. И. Нестерович, Д. А. Шиманьски // Регионарное кровообращение и микроциркуляция. – 2019. – Т. 18, № 2. – С. 19–27.Vlasov T. D., Nesterovich I. I., Shiman’ski D. A. Endothelial dysfunction: from particular to general. A return to the “old paradigm”? Regionarnoe krovoobrashchenie i mikrotsirkulyatsiya [Regional circulation and microcirculation], 2019, vol. 18, no. 2, pp. 19–27 (in Russian).Allelic polymorphism of endothelial NO-synthase gene and its functional manifestations / V. E. Dosenko [et al.] // Acta Biochimica Polonica. – 2006. – Vol. 53. – P. 299–302.Dosenko V. E., Zagoriy V. Y., Haytovich N. V., Gordok O. A., Moibenko A. A. Allelic polymorphism of endothelial NO-synthase gene and its functional manifestations. Acta Biochimica Polonica, 2006, vol. 53, pp. 299–302.Association between the ‒786T>C 1polymorphism in the promoter region of endothelial nitric oxide synthase (eNOS) and risk of coronary artery disease: a systematic review and meta-analysis / D. Liu [et al.] // Gene. – 2014. – Vol. 545, N 1. – P. 175–183. https://doi.org/10.1016/j.gene.2013.09.099Liu D., Jiang Z., Dai L. [et al]. Association between the –786T>C 1polymorphism in the promoter region of endothelial nitric oxide synthase (eNOS) and risk of coronary artery disease: a systematic review and meta-analysis. Gene, 2014, vol. 545, no. 1, pp. 175–183. https:// doi.org/10.1016/j.gene.2013.09.099Shah, R. R. Precision medicine: does ethnicity information complement genotype-based prescribing decisions? / R. R. Shah, A. Gaedigk // Ther. Adv. Drug Saf. – 2018. – Vol. 9, N 1. – P. 45–62. https://doi.org/10.1177/2042098617743393Shah R. R., Gaedigk A. Precision medicine: does ethnicity information complement genotype-based prescribing decisions? Therapeutic Advances in Drug Safety, 2018, vol. 9, no. 1, pp. 45–62. https://doi.org/10.1177/2042098617743393Petrović, J. Frequencies of clinically important CYP2C19 and CYP2D6 alleles are graded across Europe / J. Petrović, V. Pešić, V. M. Lauschke // Eur. J. Hum. Genet. – 2020. – Vol. 28, N 1. – P. 88–94. https://doi.org/10.1038/s41431-019-0480-8Petrović, J., Pešić V., Lauschke V. M. Frequencies of clinically important CYP2C19 and CYP2D6 alleles are graded across Europe. European Journal of Human Genetics, 2020, vol. 28, no. 1, pp. 88–94. https://doi.org/10.1038/s41431-019-0480-8Фармакогенетические основы индивидуальной чувствительности и персонализированного назначения антиагрегантной терапии в различных этнических группах / Б. И. Кантемирова [и др.] // Фармация и фармакология. – 2020. ‒ Т. 8, № 6. – С. 392–404.Kantemirova B. I., Orlova E. A., Polunina O. S., Chernysheva E. N., Abdullaev M. A., Sychev D. A. Pharmacogenetic basis of individual sensitivity and personalized prescription of antiplatelet therapy in various ethnic groups. Farmatsiya i farmakologiya [Pharmacy and pharmacology], 2020, vol. 8, no. 6, pp. 392–404 (in Russian). https://doi.org/10.19163/2307-9266-2020-8-6-392-404Polymorphisms of CYP2C8, CYP2C9 and CYP2C19 and risk of coronary heart disease in Russian population / A. Polonikov [et al.] // Gene. – 2017. – Vol. 627. – P. 451–459. https://doi.org/10.1016/j.gene.2017.07.004Polonikov A., Kharchenko A., Bykanova M., Sirotina S., Ponomarenko I., Bocharova A., Vagaytseva K., Stepanov V., Bushueva O., Churnosov M., Solodilova M. Polymorphisms of CYP2C8, CYP2C9 and CYP2C19 and risk of coronary heart disease in Russian population. Gene, 2017, vol. 627, pp. 451–459. https://doi.org/10.1016/j.gene.2017.07.004Возможные генетические предикторы развития сердечно-сосудистых осложнений после коронарного шунтирования / Ю. И. Гринштейн [и др.] // Кардиология. – 2018. – Т. 58, № 7. – С. 77–84. https://doi.org/10.18087/cardio.2018.7.10148Grinshtein Yu. I., Kosinova A. A., Grinshtein I. Yu., Subbotina T. N., Savchenko A. A. Possible genetic predictors of the development of cardiovascular complications after coronary bypass surgery. Kardiologiya [Cardiology], 2018, vol. 58, no. 7, pp. 77–84 (in Russian). https://doi.org/10.18087/cardio.2018.7.10148The frequencies of ten platelet polymorphisms associated with atherosclerotic cardiovascular disease in patients with venous thromboembolism: A population-based case-control study / T. Kvasnicka [et al.] // Heredit. Genet. – 2015. – Vol. 4, N 3. – Art. 153. https://doi.org/10.4172/2161-1041.1000153Kvasnicka T., Bobcikova P., Malikova I., Hajkova J., Zima T., Ulrych J. [et al.]. The frequencies of ten platelet polymorphisms associated with atherosclerotic cardiovascular disease in patients with venous thromboembolism: A population-based case-control study. Hereditary Genetics, 2015, vol. 4, no. 3, art. 153. https://doi.org/10.4172/2161-1041.1000153Страмбовская, Н. Н. Агрегационная активность тромбоцитов у носителей генетического полиморфизма GPIA (С807Т), GPIIIA (Т1565С), GPIβα (С434Т), P2RY12 (Н1/Н2), SELP (G1087A) тромбоцитарных рецепторов / Н. Н. Страмбовская // Бюл. Вост.- Сиб. науч. центра Сиб. отд-ния Рос. акад. мед. наук. – 2013. – № 6. – С. 65–70.Strambovskaya N. N. Platelet functions in healthy persons with genetic polymorphisms GPIA (С807Т), GPIIIA (Т1565С), GPIβα (С434Т), P2RY12 (Н1/Н2), SELP (G1087A) platelet receptions]. Byulleten’ Vostochno-Sibirskogo nauchnogo tsentra Sibirskogo otdeleniya Rossiiskoi akademii meditsinskikh nauk [Bulletin of the East Siberian Scientific Center of the Siberian Branch of the Russian Academy of Medical Sciences], 2013, no. 6, pp. 65–70.Ассоциация полиморфизмов генов ITGB3, P2RY12, CYP2C19 с функциональной активностью тромбоцитов у пациентов с ишемической болезнью сердца на фоне двухкомпонентной антиагрегантной терапии / Э. Ф. Муслимова [и др.] // Тер. архив. – 2017. – Т. 89, № 5. – С. 74–78.Muslimova E. F., Afanas’ev S. A., Rebrova T. Yu., Sergienko T. N., Repin A. N. Association of ITGB3, P2RY12, CYP2C19 gene polymorphisms with platelet functional activity in patients with coronary heart disease on the background of two-component antiplatelet therapy. Terapevticheskii arkhiv [Therapeutic archive], 2017, vol. 89, no. 5, pp. 74–78 (in Russian).Does i-T744C P2Y12 polymorphism modulate clopidogrel response among moroccan acute coronary syndromes patients? / H. Hassani Idrissi // Genet. Res. Int. – 2017. – Vol. 2017. – Art. ID 9532471. https://doi.org/10.1155/2017/9532471Hassani Idrissi H., Hmimech W., Khorb N. El., Akoudad H., Habbal R., Nadif S. Does i-T744C P2Y12 polymorphism modulate clopidogrel response among moroccan acute coronary syndromes patients? Genetics Research International, 2017, vol. 2017, art. ID 9532471. https://doi.org/10.1155/2017/9532471Yang, H.-H. Associations of P2Y12R gene polymorphisms with susceptibility to coronary heart disease and clinical efficacy of antiplatelet treatment with clopidogrel / H.-H. Yang, Y. Chen, C.-Y. Gao // Cardiovasc. Ther. – 2016. – Vol. 34, N 6. – P. 460–467. https://doi.org/10.1111/1755-5922.12223Yang H.-H., Chen Y., Gao C.-Y. Associations of P2Y12R gene polymorphisms with susceptibility to coronary heart disease and clinical efficacy of antiplatelet treatment with clopidogrel. Cardiovasc Therapeutics, 2016, vol. 34, no. 6, pp. 460–467. https://doi.org/10.1111/1755-5922.12223Распространенность полиморфизмов некоторых генов, связанных с функцией плазменно-тромбоцитарного звена гемостаза, при аспиринорезистентности в казахской популяции / Л. К. Каражанова [и др.] // Наука и здравоохранение. – 2018. – Т. 20, № 5. – С. 164–171.Karazhanova L. K., Zhukusheva Sh. T., Esimbekova E. I., Kapakova M. A. The prevalence of polymorphisms of some genes associated with the function of the plasma-platelet hemostasis link in aspirin resistance in the Kazakh population. Nauka i zdravookhranenie [Science and health], 2018, vol. 20, no. 5, pp. 164–171 (in Russian).The platelet polymorphism PlA2 is a genetic risk factor for myocardial infarction / E. L. Grove [et al.] // J. Inter. Med. – 2004. – Vol. 255, N 6. – P. 637–644. https://doi.org/10.1111/j.1365-2796.2004.01327.xGrove E. L., Ørntoft T. F., Lassen J. F., Jensen H. K., Kristensen S. D. The platelet polymorphism PlA2 is a genetic risk factor for myocardial infarction. Journal of Internal Medicine, 2004, vol. 255, no. 6, pp. 637–644. https://doi.org/10.1111/j.1365-2796.2004.01327.xFloyd, C.N. The PlA1/A2 polymorphism of glycoprotein IIIa as a risk factor for myocardial infarction: A meta-analysis / C. N. Floyd, A. Mustafa, A. Ferro // PLОS ONE. – 2014. ‒ Vol. 9, N 7. – P. e101518. https://doi.org/10.1371/journal.pone.0101518Floyd C. N., Mustafa A., Ferro A. The PlA1/A2 polymorphism of glycoprotein IIIa as a risk factor for myocardial infarction: A meta-analysis. PLOS ONE, 2014, vol. 9, no. 7, p. e101518. https://doi.org/10.1371/journal.pone.0101518Clinical significance of Platelet Antigen 1/Platelet Antigen 2 (PlA1/A2) polymorphism of integrin β 3 (ITGB3) gene in coronary artery disease / Al. H. Abdel [et al.] // Med. J. Cairo Univ. – 2019. – Vol. 87, N 6. – P. 3969–3975. https://doi.org/10.21608/MJCU.2019.70350Abdel Al. H., Bawady S. A., Saab A. A., Kilany W. El., Allam A. S., Metwally S. S. Clinical significance of Platelet Antigen 1/ Platelet Antigen 2 (PlA1/A2) polymorphism of integrin β 3 (ITGB3) gene in coronary artery disease. Medical Journal of Cairo University, 2019, vol. 87, no. 6, pp. 3969–3975. https://doi.org/10.21608/MJCU.2019.70350GPIa polymorphisms are associated with outcomes in patients at high cardiovascular risk / D. Rath [et al.] // Front. Cardiovasc. Med. – 2017. – Vol. 4, art. 52. https://doi.org/10/3389/fcvm.2017.00052Rath D., Schaeffeler E., Winter S., Levertov S., Müller K., Droppa M., Stimpfle F., Langer H. F., Gawaz M., Schwab M., Geisler T. GPIa polymorphisms are associated with outcomes in patients at high cardiovascular risk. Frontiers in Cardiovascular Medicine, 2017, vol. 4, art. 52. https://doi.org/10.3389/fcvm.2017.00052Значимость полиморфизма С807T гена рецептора к коллагену ITGA2 и агрегационной активности тромбоцитов у пациентов с артериальной гипертензией / Е. А. Шишкина [и др.] // Казан. мед. журн. – 2019. – Т. 100, № 3. – С. 386–391.Shishkina E. A., Khlynova O. V., Vasilets L. M., Sakhena V., Krivtsov A. V. Significance of C807T polymorphism of ITGA2 collagen receptor gene and platelet aggregation activity in patients with arterial hypertension. Kazanskii meditsinskii zhurnal [Kazan medical journal], 2019, vol. 100, no. 3, pp. 386–391 (in Russian).Glycoprotein Ia C807T: Polymorphisms and their association with platelet function in patients with the acute coronary syndrome / Q. Zhang [et al.] // Cardiology. – 2015. – Vol. 132, N 4. – P. 213–220. https://doi.org/10.1159/000435906Zhang Q., Jin Y., Shi D., Gong J., Liu J., Lu Y., Tong M., Wang J., Song Q., Dong J., Chen W., Lv K. Glycoprotein Ia C807T: Polymorphisms and their association with platelet function in patients with the acute coronary syndrome. Cardiology, 2015, vol. 132, no. 4, pp. 213–220. https://doi.org/10.1159/000435906Lack of association between the platelet glycoprotein Ia C807T gene polymorphism and coronary artery disease: a meta-analysis / A. E. Tsantes [et al.] // Int. J. Cardiol. – 2007. – Vol. 118, N 2. – P. 189–196. https://doi.org/10.1016/j.ijcard.2006.06.047Tsantes A. E., Georgios K., Nikolopoulos G. K., Bagos P. G., Vaiopoulos G., Travlou A. Lack of association between the platelet glycoprotein Ia C807T gene polymorphism and coronary artery disease: a meta-analysis. International Journal of Cardiology, 2007, vol. 118, no. 2, pp. 189–196. https://doi.org/10.1016/j.ijcard.2006.06.047Генотип ‒786CC гена эндотелиальной NO-синтазы NOS3 как фактор неблагоприятного течения ишемической болезни сердца и риска повышенной агрегации тромбоцитов на фоне приема антиагрегантов / Э. Ф. Муслимова [и др.] // Рос. кардиол. журн. – 2017. – № 10. – С. 29–32.Muslimova E. F., Rebrova T. Yu., Afanas’ev S. A., Sergienko T. N., Repin A. N. Genotype ‒786CC of the endothelial NO-synthase gene NOS3 as a factor in the adverse course of coronary heart disease and the risk of increased platelet aggregation while taking antiplatelet agents. Rossiiskii kardiologicheskii zhurnal = Russian journal of cardiology, 2017, vol. 10, pp. 29–32 (in Russian).Short-term clinical outcomes in patients with acute myocardial infarction after successful percutaneous coronary revascularization: the role of promoter polymorphism of the endothelial nitric oxide synthase gene / O. Petyunina [et al.] // Biomed. Res. Ther. – 2019. ‒ Vol. 6, N 5. ‒ P. 3166–3179. https://doi.org/10.15419/bmrat.v6i5.543Petyunina O., Kopytsy M., Babichev D., Berezin A. Short-term clinical outcomes in patients with acute myocardial infarction after successful percutaneous coronary revascularization: the role of promoter polymorphism of the endothelial nitric oxide synthase gene. Biomedical Research and Therapy, 2019, vol. 6, no. 5, pp. 3166–3179. https://doi.org/10.15419/bmrat.v6i5.543Li, X. Associations between eNOS gene polymorphisms and the risk of coronary artery disease: a systematic review and metaanalysis of 132 case-control studies / X. Li, Y. Lin, R. Zhang // Eur. J. Prev. Cardiol. – 2019. – Vol. 26. – P. 160–170. https://doi.org/10.1177/2047487318780748Li X., Lin Y., Zhang R. Associations between eNOS gene polymorphisms and the risk of coronary artery disease: a systematic review and meta-analysis of 132 case-control studies. European Journal of Preventive Cardiology, 2019, vol. 26, pp. 160–170. https://doi.org/10.1177/2047487318780748Анализ влияния структурной перестройки промотора гена NOS3 на продукцию вазоактивных эндотелиальных факторов / А. В. Хромова [и др.] // Вестн. Сев. (Аркт.) фед. ун-та. Сер. Мед.-биол. науки. – 2015. – № 4. – С. 107–115.Khromova A. V., Feliksova O. M., Kuba A. A., Bebyakova N. A. Analysis of the effect of structural rearrangement of the NOS3 gene promoter on the production of vasoactive endothelial factors. Vestnik Severnogo (Arkticheskogo) Federal’nogo universiteta. Seriya: Medikobiologicheskie nauki [Bulletin of the Northern (Arctic) Federal University. Series: Medical and biological sciences], 2015, no. 4, pp. 107–115 (in Russian).Сметник, В. П. Женские половые гормоны и сердечно-сосудистая система / В. П. Сметник, А. А. Сметник // Мед. совет. – 2011. – № 3–4. – С. 40–45.Smetnik V. P., Smetnik A. A. Female sex hormones and the cardiovascular system. Meditsinskii sovet [Medical council], 2011, no. 3–4, pp. 40–45 (in Russian).Бебякова, Н. А. Влияние полиморфизма -786Т>C гена eNOS на параметры гемодинамики у девушек / Н. А. Бебякова, Н. А. Фадеева, А. В. Хромова // Журн. мед.-биол. исслед. – 2018. ‒ Т. 6, № 3. – С. 205–213.Bebyakova N. A., Fadeeva N. A., Khromova A. V. Effect of ‒786T>C polymorphism of the eNOS gene on hemodynamic parameters in girls. Zhurnal mediko-biologicheskikh issledovanii [Journal of biomedical research], 2018, vol. 6, no. 3, pp. 205–213.Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause / J. E. Rossouw [et al.] // JAMA. – 2007. – Vol. 297, N 13. – Р. 1465–1477. https://doi.org/10.1001/jama.297.13.1465Rossouw J. E., Prentice R. L., Manson J. E., Wu L., Barad D., Barnabei V. M., Ko M., La Croix A. Z., Margolis K. L., Stefanick M. L. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA, 2007, vol. 297, no. 13, pp. 1465–1477. https://doi.org/10.1001/jama.297.13.1465

The authors declare that there are no conflicts of interest present.